New drug B001 tested for rare autoimmune disease
NCT ID NCT05145361
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug called B001 in 45 people with a rare autoimmune disease called NMOSD. The study aims to check if B001 is safe, how the body processes it, and whether it might help control the disease. Participants must have had at least one relapse in the past year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B001 injection
What this could lead to
If successful, this could point toward a new treatment option to control NMOSD and reduce relapses.
What could go wrong
This is a very early, small Phase 1b trial focused on safety and dosing. It may not show clear benefit, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMO SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
First Hospital of Shanxi Medical University
RECRUITINGTaiyuan, Shanxi, 030001, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tangdu hospital,fourth military medical university
RECRUITINGXi’an, Shanxi, 710038, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Tianjin Municipality, 300052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact